Results Generated From:
Embase <1980 to 2012 Week 32>
Embase (updates since 2012-08-03)
<1>
Accession Number
2012441583
Authors
Tung H.-H. Shen S.-F. Shih C.-C. Chiu K.-M. Lee J.-Y. Liu C.-Y.
Institution
(Tung) Tungs' Taichung MetroHabor Hospital, National Taipei University of
Nursing and Health Science, 365 Ming Te Road PeiTou, Taipei 112, Taiwan
(Republic of China)
(Shen) Buddish Tzu-Chi General Hospital, National Taipei University of
Nursing and Health Science, 365 Ming Te Road PeiTou, Taipei 112, Taiwan
(Republic of China)
(Shih) Cardiovascular Division, Taipei Veterans General Hospital, 201,
Sec. 2, Shih-Pai Road, PeiTou, Taipei 11217, Taiwan (Republic of China)
(Chiu) Cardiovascular Surgery Division, Far Eastern Memorial Hospital, No.
21, Sec. 2, Nanya S. Road, Banqiao Dist., New Taipei City 220, Taiwan
(Republic of China)
(Lee) Cardiovascular Department, Mackay Memorial Hospital, No. 92, Sec. 2,
Zhongshan N. Road, Zhongshan Dist., Taipei City 10449, Taiwan (Republic of
China)
(Liu) National Taipei University of Nursing and Health Science, 365 Ming
Te Road PeiTou, Taipei 112, Taiwan (Republic of China)
Title
Effects of a preoperative individualized exercise program on selected
recovery variables for cardiac surgery patients: A pilot study.
Source
Journal of the Saudi Heart Association. 24 (3) (pp 153-161), 2012. Date of
Publication: July 2012.
Publisher
Elsevier (P.O. Box 211, Amsterdam 1000 AE, Netherlands)
Abstract
Objective: Research on preoperative individualized exercise prescription
(PIEP) for heart surgery patients in Taiwan is lacking. Thus, the purpose
of this study was to examine the feasibility of a PIEP in the Taiwanese
population. Method: A quasi-experimental design, using purposive sampling,
was conducted. Thirty-five patients were recruited, of whom 15 chose to
participate in the experimental (PIEP training plus usual care) group, and
20 chose to participate in the control (usual care) group. The effects of
the intervention were determined by pulmonary complication-related
parameters and quality of life. Results and conclusion: The development
and process of PIEPs suitable for cardiac patients was described in this
study. The results reveal that the two-week exercise-training program
contributed to a decreased peak respiratory exchange ratio (RER) after the
surgery and earlier ambulation. The effectiveness of PIEPs in improving
the quality of life in cardiac surgery patients was validated. This study
may also contribute as a reference of the PIEP effect on patients to the
healthcare providers. 2012 King Saud University.
<2>
[Use Link to view the full text]
Accession Number
2012437325
Authors
Mulligan C. Beghetti M.
Institution
(Mulligan) Research Evaluation Unit, Oxford PharmaGenesis Limited, Oxford,
United Kingdom
(Beghetti) Pediatric Cardiology Unit, Department of the Child and
Adolescent, Children's University Hospital, Geneva, Switzerland
Title
Inhaled iloprost for the control of acute pulmonary hypertension in
children: A systematic review.
Source
Pediatric Critical Care Medicine. 13 (4) (pp 472-480), 2012. Date of
Publication: July 2012.
Publisher
Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327,
Philadelphia PA 19106-3621, United States)
Abstract
OBJECTIVE: Inhaled iloprost is attracting growing interest as a potential
alternative and/or adjuvant to inhaled nitric oxide in the management of
pediatric pulmonary hypertension in the acute and intensive care settings.
However, there are currently no formal evidence-based guidelines regarding
the use of inhaled iloprost in children with pulmonary hypertension. The
aim of this systematic review is to assess the literature concerning the
use of inhaled iloprost in children with pulmonary hypertension in the
acute setting. DATA SOURCES: Studies were identified from PubMed and
Embase. Internal literature databases and recent congress abstracts (2009
onward) were also searched for relevant publications. STUDY SELECTION:
Studies were included if they examined the use of inhaled iloprost in
children with pulmonary hypertension in an acute or intensive care
setting. DATA EXTRACTION AND SYNTHESIS: Twenty-eight studies were included
in the review. The majority were case studies or case series (n = 17), and
in total, the 28 studies represented the treatment of 195 children with
iloprost. Iloprost was most frequently studied in children undergoing
cardiac surgery (as a bridge to surgery and postoperatively), in children
undergoing acute pulmonary vasoreactivity testing, and in neonates with
persistent pulmonary hypertension of the newborn. The results of the
included studies suggested that inhaled iloprost may have a diverse role
in the acute treatment of pediatric pulmonary hypertension and that its
acute effects are similar to those of inhaled nitric oxide. However, the
iloprost dose was not consistently reported and varied greatly between
studies, and several different administration devices were used.
CONCLUSIONS: Inhaled iloprost may be useful in the acute treatment of
children and neonates with pulmonary hypertension, but clinical data are
scarce, and the appropriate dosing of iloprost in different scenarios is
uncertain. Well-designed prospective clinical trials are needed. Copyright
2012 by the Society of Critical Care Medicine and the World Federation of
Pediatric Intensive and Critical Care Societies.
<3>
Accession Number
22314458
Authors
Dhar S. Rahman Z. Hasan K. Hoque M.F. Sultana A.
Institution
(Dhar) Upazila Health Complex, Hathazari, Chittagong, Bangladesh.
Title
Effect of pre-bypass methylprednisolone on post-operative renal function
following correction of atrial septal defect under cardiopulmonary bypass.
Source
Mymensingh medical journal : MMJ. 21 (1) (pp 72-79), 2012. Date of
Publication: Jan 2012.
Abstract
Conventional open heart surgery with cardiopulmonary bypass (CPB) are
associated with transient post-operative renal dysfunction which is caused
by systemic inflammatory response induced by CPB. Corticosteroids are
administered to attenuate the systemic inflammatory response. The purpose
of this study was to compare the effects of pre-bypass and post-bypass
methylprednisolone on postoperative renal function after correction of ASD
under CPB. Forty (40) patients were selected in the University cardiac
centre of BSMMU undergoing ASD correction under CPB. Patients were
randomized into two group to receive pre-bypass (Group A) or post-bypass
(Group B) methylprednisolone 30mg/kg. Markers of glomerular function (BUN,
serum creatinine, creatinine clearance) and damage (micro-albuminuria) and
tubular function (glucosuria) were evaluated 24 hours after operation.
Transient impairment of glomerular and tubular function of kidney was
observed in patients those received post-bypass metylprednisolone (Group
B) while Group A patients shown no significant difference between baseline
and post-operative renal function. Use of pre-bypass methylprednisolone
has a protective effect on post-operative renal function after correction
of ASD under CPB.
<4>
Accession Number
2012436852
Authors
Hofma S.H. Brouwer J. Velders M.A. Van'T Hof A.W.J. Smits P.C. Quere M. De
Vries C.J. Van Boven A.J.
Institution
(Hofma, Brouwer, Velders, Quere, De Vries, Van Boven) Cardiology, Medical
Center Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, Netherlands
(Van'T Hof) Isala Clinics, Zwolle, Netherlands
(Smits) Maasstad Hospital Rotterdam, Netherlands
Title
Second-generation everolimus-eluting stents versus first-generation
sirolimus-eluting stents in acute myocardial infarction: 1-year results of
the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for
acute myocardial infarction) trial.
Source
Journal of the American College of Cardiology. 60 (5) (pp 381-387), 2012.
Date of Publication: 31 Jul 2012.
Publisher
Elsevier USA (6277 Sea Harbor Drive, Orlando FL 32862 8239, United States)
Abstract
Objectives: The goal of this study was to compare the efficacy and safety
of second-generation everolimus-eluting stents (EES) with first-generation
sirolimus-eluting stents (SES) in primary percutaneous coronary
intervention (PCI) for acute myocardial infarction (AMI). Background:
Drug-eluting stents (DES) in AMI are still feared for possible late and
very late stent thrombosis (ST). Newer-generation DES, with more
hemocompatible polymers and improved healing, may show promise regarding
increased efficacy of DES with improved safety. However, no randomized
trials in AMI are available. Methods: A total of 625 patients with AMI
were randomized (2:1) to receive EES or SES in the XAMI (XienceV Stent vs
Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
Primary endpoint was major adverse cardiac events (MACE) at 1 year
consisting of cardiac death, nonfatal AMI, or any target vessel
revascularization. The study was powered for noninferiority of EES.
Secondary endpoints comprised ST rates and MACE rate up to 3 years.
Results: The MACE rate was 4.0% for EES and 7.7% for SES; the absolute
difference was -3.7% (95% confidence interval: -8.28 to -0.03; p = 0.048)
and relative risk was 0.52 (95% confidence interval: 0.27 to 1.00).
One-year cardiac mortality was low at 1.5% for EES versus 2.7% for SES (p
= 0.36), and 1-year incidence of definite and/or probable ST was 1.2% for
EES versus 2.7% for SES (p = 0.21). Conclusions: In this all-comer,
randomized, multicenter AMI trial, second-generation EES was noninferior
to SES, and superiority for MACE was suggested. ST rate in EES at 1-year
was low, but long-term follow-up and larger studies will have to show
whether very late ST rates will also be improved in newer DES. (XienceV
Stent vs Cypher Stent in Primary PCI for Acute Myocardial Infarction
[XAMI]; NTR1123) 2012 American College of Cardiology Foundation.
<5>
Accession Number
2012435176
Authors
Riber L.P. Christensen T.D. Jensen H.K. Hoejsgaard A. Pilegaard H.K.
Institution
(Riber, Christensen, Hoejsgaard, Pilegaard) Department of Cardiothoracic
and Vascular Surgery, Institute of Clinical Medicine, Aarhus University
Hospital, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark
(Jensen) Department of Cardiology, Institute of Clinical Medicine, Aarhus
University Hospital, Aarhus, Denmark
Title
Amiodarone significantly decreases atrial fibrillation in patients
undergoing surgery for lung cancer.
Source
Annals of Thoracic Surgery. 94 (2) (pp 339-346), 2012. Date of
Publication: August 2012.
Publisher
Elsevier USA (6277 Sea Harbor Drive, Orlando FL 32862 8239, United States)
Abstract
Background: Postoperative atrial fibrillation occurs in 5% to 65% of
patients undergoing thoracic surgery. Although postoperative atrial
fibrillation often is regarded as a temporary, benign, operation-related
problem, it is associated with a twofold to threefold increase in risk of
adverse events, including transient or permanent stroke, acute myocardial
infarction, and death. Methods: A total of 254 consecutively eligible
enrolled patients undergoing surgery for lung cancer were included in this
randomized, controlled, double-blinded trial. Patients received 300 mg of
amiodarone or placebo intravenously over 20 minutes immediately after
surgery and an oral dose of 600 mg of amiodarone or placebo twice daily
during the first 5 postoperative days. Results: The patients in the
amiodarone prophylaxis group had a reduction in the risk of atrial
fibrillation of 23% (12 to 31); number needed to treat was 4.4 (3.1 to
7.8). A total of 38 in the control group and 11 in the amiodarone group
experienced atrial fibrillation (p < 0.001). Adverse effects were observed
in 10 patients equally distributed in both trial arms. Conclusions:
Postoperative prophylaxis with a high dose of oral amiodarone after an
intravenous bolus infusion is a safe, practical, feasible, and effective
regimen for patients with lung cancer undergoing surgery. It significantly
reduced the incidence of postoperative atrial fibrillation. 2012 The
Society of Thoracic Surgeons.
<6>
Accession Number
2012426556
Authors
Puri R. Kapadia S.R. Nicholls S.J. Harvey J.E. Kataoka Y. Tuzcu E.M.
Institution
(Puri, Kapadia, Nicholls, Harvey, Kataoka, Tuzcu) Department of
Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic,
9500 Euclid Avenue, Cleveland, OH 44195-0001, United States
Title
Optimizing outcomes during left main percutaneous coronary intervention
with intravascular ultrasound and fractional flow reserve: The current
state of evidence.
Source
JACC: Cardiovascular Interventions. 5 (7) (pp 697-707), 2012. Date of
Publication: July 2012.
Publisher
Elsevier Inc. (360 Park Avenue South, New York NY 10010, United States)
Abstract
Percutaneous coronary intervention (PCI) is an evolving indication for the
treatment of unprotected left main coronary arterial (UMLCA) stenoses in
selected individuals. Intravascular ultrasound (IVUS)-guided PCI within
the epicardial coronary tree has been shown to improve acute procedural
results and subsequent clinical outcomes. Similarly, fractional flow
reserve (FFR) is rapidly gaining popularity as a means to guide the
coronary interventionalist to embark upon a "physiological-based"
revascularization strategy. In light of the emergence of PCI for ULMCA
stenoses, the lack of randomized trials has meant that there are no
systematic guidelines that advocate the routine use of these adjunctive
imaging techniques to optimize procedural and clinical outcomes. Given the
potential dire clinical consequences of procedural failure during ULMCA
PCI, in this review we systematically address the current level of
evidence for the use of FFR and IVUS during the assessment for and
undertaking of PCI for ULMCA stenoses. In lieu of the current available
level of evidence, we recommend the use of FFR for the assessment of
(angiographic indeterminate) isolated ostial or midshaft left main
coronary arterial (LMCA) stenoses in patients who are considered more
appropriate candidates for coronary arterial bypass grafting. In those
patients with distal/bifurcation LMCA lesions and in those with
diffuse/distal coronary arterial disease, we strongly recommend the
liberal use of IVUS. Furthermore, in those patients considered likely
candidates for ULMCA PCI, IVUS remains crucial for assessing the degree of
lumen compromise and the extent, distribution, and morphology of plaque as
well as for the immediate postprocedural quantification of stent
deployment. 2012 by the American College of Cardiology Foundation.
<7>
Accession Number
2012432283
Authors
Ben-Dor I. Looser P.M. Maluenda G. Weddington T.C. Kambouris N.G. Barbash
I.M. Hauville C. Okubagzi P. Corso P.J. Satler L.F. Pichard A.D. Waksman
R.
Institution
(Ben-Dor, Looser, Maluenda, Weddington, Kambouris, Barbash, Hauville,
Okubagzi, Corso, Satler, Pichard, Waksman) Washington Hospital Center,
Washington, DC 20010, United States
Title
Transcatheter aortic valve replacement under monitored anesthesia care
versus general anesthesia with intubation.
Source
Cardiovascular Revascularization Medicine. 13 (4) (pp 207-210), 2012. Date
of Publication: July 2012.
Publisher
Elsevier Inc. (360 Park Avenue South, New York NY 10010, United States)
Abstract
Aims: Most transcatheter aortic valve replacement (T-AVR) using the
Edwards SAPIEN transcatheter heart valve (Edwards Lifesciences, Irvine,
CA) is done under general anesthesia. The present study aimed to examine
the feasibility and safety of T-AVR under monitored anesthesia care and
aimed to compare the clinical outcome to the outcome of patients who
underwent general anesthesia. Methods: The analysis included 92
consecutive patients undergoing T-AVR via the transfemoral approach guided
by transesophageal echocardiography using the Edwards SAPIEN valve. The
cohort was divided into two groups: I, monitored anesthesia care (n=70;
76.1%) and II, intubation (n=22; 23.9%). Monitored anesthesia care was
given by anesthesiologists in one of two protocol regimens: Ketamine &
Propofol or Dexmedetomidine. The crossover rate to general anesthesia and
the clinical outcome of these two groups were compared. Results: Baseline
clinical characteristics of the two groups were similar, except for higher
logistic EuroSCORE and prior stroke in the monitored anesthesia care
group. Surgical access of the femoral artery was performed in 15 (68.1%)
from the general anesthesia group and in 24 (34.2%) from the monitored
anesthesia care group, p. =0.05. The median procedure duration was
significantly lower in the monitored anesthesia care group (91 vs. 155min,
p. =0.008) and there was a trend to lower median intensive care unit stay
and hospital stay (27 vs. 72h, p. =0.07 and 5 vs. 7.5days, p. =0.06,
respectively). Of the patients with monitored anesthesia care, 8 (11.4%)
converted to general anesthesia. Conclusion: T-AVR using the Edwards
SAPIEN valve can be performed in the majority of cases with controlled
monitored anesthesia care, thereby avoiding the necessity of general
anesthesia and resulting in shorter procedure time and in-hospital length
of stay. 2012.
<8>
Accession Number
2012423353
Authors
Arazi H.C. Carnevalini M. Falconi E. Ovejero R. Giorgi M. Caroli C. Nojek
C. Badimon J.J.
Institution
(Arazi, Giorgi, Caroli, Nojek) Sociedad Argentina de Cardiologia,
Argentina
(Arazi, Carnevalini, Falconi, Ovejero, Giorgi, Caroli, Nojek) Departamento
de Cardiologia y Cirugia Cardiovascular, FLENI, Argentina
(Badimon) Mount Sinai School of Medicine, NY, United States
Title
The association of antiplatelet aggregation effect of aspirin and platelet
count. Possible dosage implications.
Source
Revista Argentina de Cardiologia. 80 (2) (pp 114-120), 2012. Date of
Publication: April 2012.
Publisher
Sociedad Argentina de Cardiologia (Azcuenaga 980, Ciudad Autonoma de
Buenos Aires C1115AAD, Argentina)
Abstract
Background Thirty percent of patients do not achieve an adequate
anti-platelet effect despite therapy with aspirin (ASA) 100 mg/d after
coronary artery bypass-graft surgery (CABGS), probably due to reduced
inhibitory effect of ASA, increased platelet activation and increased
platelet turnover secondary to the surgical procedure. Objectives To
evaluate the relation between platelet count and lower antiplatelet effect
and to determine if antiaggregation improves by dividing the dose of ASA.
Material and Methods A total of 50 patients undergoing CABGS (with an
average of 2.95 grafts per surgery) were randomly assigned to three groups
depending on the dose of ASA indicated: G100 (100 mg/d, n=18 patients),
G300 (300 mg/d, n=14) and G100x3 (100 mg TID, n=18). All the patients
received 100 mg/d before surgery. Platelet reactivity was assessed by
whole blood impedance using arachidonic acid before surgery (T0), 24 h
(T1), 72 h (T2), 7 days (T3), and one month post-CABG (T4). Results Before
surgery, all patients had optimal values of antiaggregation (0 W). During
the postoperative period, antiaggregation values were better in patients
from G100x3 (p <0.05). No patients in G100x3 had values >=6 W, which
correspond to those of healthy subjects who do not receive ASA. This value
was observed in 5 patients (28%) from G100 and 4 patients (29%) from G300.
The association between antiaggregation and platelet turnover was
statistically significant (R2=0.57; p=0.001). A daily turnover >20% was
related with values of platelet aggregation >=6 W; OR=2.1 (CI 1.8-4.21;
p=0.0028). Conclusions In patients undergoing CABGS, the lowest
antiplatelet effect of ASA was associated with the highest platelet
turnover. A better antiaggregation might be achieved by dividing therapy
in low dose of ASA.
<9>
Accession Number
2012404498
Authors
Velazquez E.J. Lee K.L. Deja M.A. Jain A. Sopko G. Marchenko A. Ali I.S.
Pohost G. Gradinac S. Abraham W.T. Yii M. Prabhakaran D. Szwed H. Ferrazzi
P. Petrie M.C. O'Connor C.M. Panchavinnin P. She L. Bonow R.O. Rankin G.R.
Jones R.H. Rouleau J.-L.
Institution
(Velazquez, O'Connor) Division of Cardiovascular Medicine, Duke University
Medical Center, Durham, NC, United States
(Lee) Departments of Biostatistics and Bioinformatics, Duke University
Medical Center, Durham, NC, United States
(Jones) Department of Surgery, Duke University Medical Center, Durham, NC,
United States
(Velazquez, She, Rankin) Duke Clinical Research Institute, Duke University
Medical Center, 2400 Pratt St., Durham, NC 27705, United States
(Deja) Second Department of Cardiac Surgery, Medical University of
Silesia, Katowice, Poland
(Szwed) National Institute of Cardiology, Warsaw, Poland
(Jain) SAL Hospital and Medical Institute, Ahmedabad, India
(Prabhakaran) Center for Chronic Disease Control, New Delhi, India
(Sopko) Division of Cardiovascular Sciences, National Heart, Lung, and
Blood Institute, Bethesda, MD, United States
(Marchenko) Research Institute of Circulation Pathology, Novosibirsk,
Russian Federation
(Ali) Division of Cardiac Surgery, Dalhousie University, Queen Elizabeth
II Health Sciences Centre, Halifax, NS, Canada
(Pohost) Keck School of Medicine, Viterbi School of Engineering,
University of Southern California, Los Angeles, United States
(Gradinac) Dedinje Cardiovascular Institute, University of Belgrade School
of Medicine, Belgrade, Serbia
(Abraham) Division of Cardiovascular Medicine, Ohio State University,
Columbus, United States
(Yii) Departments of Cardiothoracic Surgery and Surgery, University of
Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia
(Ferrazzi) Dipartimento Cardiovascolare Clinico e di Ricerca, Ospedali
Riuniti Bergamo, Bergamo, Italy
(Petrie) Scottish National Advanced Heart Failure Service, Golden Jubilee
National Hospital, Glasgow, United Kingdom
(Panchavinnin) Siriraj Hospital, Mahidol University, Bangkok, Thailand
(Bonow) Division of Cardiology, Northwestern University, Chicago, United
States
(Rouleau) Montreal Heart Institute, Montreal, Canada
Title
Coronary-artery bypass surgery in patients with left ventricular
dysfunction.
Source
New England Journal of Medicine. 364 (17) (pp 1607-1616), 2011. Date of
Publication: 28 Apr 2011.
Publisher
Massachussetts Medical Society (860 Winter Street, Waltham MA 02451-1413,
United States)
Abstract
BACKGROUND: The role of coronary-artery bypass grafting (CABG) in the
treatment of patients with coronary artery disease and heart failure has
not been clearly established. METHODS: Between July 2002 and May 2007, a
total of 1212 patients with an ejection fraction of 35% or less and
coronary artery disease amenable to CABG were randomly assigned to medical
therapy alone (602 patients) or medical therapy plus CABG (610 patients).
The primary outcome was the rate of death from any cause. Major secondary
outcomes included the rates of death from cardiovascular causes and of
death from any cause or hospitalization for cardiovascular causes.
RESULTS: The primary outcome occurred in 244 patients (41%) in the
medical-therapy group and 218 (36%) in the CABG group (hazard ratio with
CABG, 0.86; 95% confidence interval [CI], 0.72 to 1.04; P = 0.12). A total
of 201 patients (33%) in the medical-therapy group and 168 (28%) in the
CABG group died from an adjudicated cardiovascular cause (hazard ratio
with CABG, 0.81; 95% CI, 0.66 to 1.00; P = 0.05). Death from any cause or
hospitalization for cardiovascular causes occurred in 411 patients (68%)
in the medical-therapy group and 351 (58%) in the CABG group (hazard ratio
with CABG, 0.74; 95% CI, 0.64 to 0.85; P<0.001). By the end of the
follow-up period (median, 56 months), 100 patients in the medical-therapy
group (17%) underwent CABG, and 555 patients in the CABG group (91%)
underwent CABG. CONCLUSIONS: In this randomized trial, there was no
significant difference between medical therapy alone and medical therapy
plus CABG with respect to the primary end point of death from any cause.
Patients assigned to CABG, as compared with those assigned to medical
therapy alone, had lower rates of death from cardiovascular causes and of
death from any cause or hospitalization for cardiovascular causes. (Funded
by the National Heart, Lung, and Blood Institute and Abbott Laboratories;
STICH ClinicalTrials.gov number, NCT00023595.) Copyright 2011
Massachusetts Medical Society.
No comments:
Post a Comment